Improved pharmacokinetics of AMG 517 through co-crystallization part 2: Analysis of 12 carboxylic acid co-crystals

Journal of Pharmaceutical Sciences

Volumn 100, Issue 7, 2011, Pages 2734-2743

  Stanton, Mary K ^a   Kelly, Ron C ^a   Colletti, Adria ^a   Langley, Meghan ^a   Munson, Eric J ^b   Peterson, Matthew L ^a   Roberts, John ^a   Wells, Mary ^a  

^a AMGEN INC   (United States)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

Co crystals; Dissolution; Formulation; Pharmacokinetics; Solubility

Indexed keywords

CARBOXYLIC ACID; N [4 [6 [4 (TRIFLUOROMETHYL)PHENYL] 4 PYRIMIDINYLOXY]BENZOTHIAZOL 2 YL]ACETAMIDE; POVIDONE; SORBIC ACID;

ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; DRUG FORMULATION; DRUG SOLUBILITY; IN VITRO STUDY; INTESTINE FLUID; MALE; NONHUMAN; RAT;

EID: 79955594268     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22502     Document Type: Article

References (19)

1. Stanton MK, Kelly RC, Colletti A, Kiang Y-H, Langley M, Munson EJ, Peterson ML, Roberts J, Wells M. 2010. Improved pharmacokinetics of AMG 517 through co-crystallization. Part 1: Comparison of two acids with corresponding amide co-crystals. J Pharm Sci 99(9):3769-3778.
2. Peterson ML, Stanton MK, Kelly RC, Staples R, Cheng A. 2010. Preparation, solid state characterization, and single crystal structure analysis of N-(4-(6-(4-(trifluoromethyl)phenyl)pyrimidin-4-yloxy)benzo[d]thiasol-2-yl)acetamide crystal forms. Cryst Eng Comm DOI:10.1039/C1030CE00544D. In press.
3. Bak A, Gore A, Yanez E, Stanton M, Tufekcic S, Syed R, Akrami A, Rose M, Surapaneni S, Bostick T, et al. 2008. The co-crystal approach to improve the exposure of a water-insoluble compound: AMG 517 sorbic acid co-crystal characterization and pharmacokinetics. J Pharm Sci 97(9):3942-3956.
4. ACD, Inc. ACD/pKa DB v12.0. ACD/pKa DB v120. Toronto, Canada: ACD, Inc.
5. Peterson ML, Hickey MB, Zaworotko MJ, Almarsson Ö. 2006. Expanding the scope of crystal form evaluation in pharmaceutical science. J Pharm Pharm Sci 9(3):317-326.
6. Stanton MK, Bak A. 2008. Physicochemical properties of pharmaceutical co-crystals: A case study of ten AMG 517 co-crystals. Cryst Growth Des 8(10):3856-3862.
7. Stanton MK, Tufekcic S, Morgan C, Bak A. 2009. Drug substance and former structure property relationships in 15 diverse pharmaceutical co-crystals. Cryst Growth Des 9(3):1344-1352.
8. Morris KR, Fakes MG, Thakur AB, Newman AW, Singh AK, Venit JJ, Spagnuolo CJ, Serajuddin ATM. 1994. An integrated approach to the selection of optimal salt form for a new drug candidate. Int J Pharm 105:209-217.
9. Saxena V, Panicucci R, Joshi Y, Garad S. 2009. Developability assessment in pharmaceutical industry: An integrated group approach for selecting developable candidates. J Pharm Sci 98(6):1962-1979.
10. Engel GL, Farid NA, Faul MM, Richardson LA, Winneroski LL. 2000. Salt form selection and characterization of LY333531 mesylate monohydrate. Int J Pharm 198:239-247.
11. Hirsch CA, Messenger RJ, Brannon JL. 1978. Fenoprofen: Drug form selection and preformulation stability studies. J Pharm Sci 67(2):231-236.
12. Guzmán HR, Tawa M, Zhang Z, Ratanabanangkoon P, Shaw P, Gardner CR, Chen H, Moreau J-P, Almarsson Ö, Remenar JF. 2007. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J Pharm Sci 96(10):2686-2700.
13. Meyer MC, Straughn AB, Mhatre RM, Shah VP, Williams RL, Lesko LJ. 1998. The relative bioavailability and in vivo-in vitro correlations for four marketed carbamazepine tablets. Pharm Res 15(11):1787-1791.
14. Dressman JB, Amidon GL, Reppas C, Shah VP. 1998. Dissolution testing as a prognostic tool for oral drug absorption: Immediate release dosage forms. Pharm Res 15(1):11-22.
15. Doherty EM, Fotsch C, Bannon AW, Bo Y, Chen N, Dominguez C, Falsey J, Gavva NR, Katon J, Nixey T, et al. 2007. Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate. J Med Chem 50(15):3515-3527.
16. Cheney ML, Shan N, Healey ER, Hanna M, Wojtas L, Zaworotko MJ, Sava V, Song S, Sanchez-Ramos JR. 2010. Effects of crystal form on solubility and pharmacokinetics: A crystal engineering case study of lamotrigine. Cryst Growth Des 10(1):394-405.
17. Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharm Res 10(7):1093-1095.
18. Stevens LE, Missel PJ, Weiner AL. 2008. Controlled flow-through dissolution methodology: A high performance system. Pharm Dev Tech 13:135-153.
19. Collier JW, Thakare M, Garner ST, Israel B, Ahmed H, Granade S, Strong DL, Price JC, Capomacchia AC. 2009. Accelerated dissolution testing for controlled release microspheres using the flow-through dissolution apparatus. Pharm Dev Tech 14:9-17.